- Facts included
- The Food and Drug Administration (FDA or Agency) is withdrawing approval of abbreviated new drug application (ANDA) 208833 for Celecoxib capsules, 50 milligrams (mg), 100 mg, 200 mg, and 400 mg, held by Amneal Pharmaceuticals of New York, LLC.
- Amneal requested withdrawal of approval of this application and has waived its opportunity for a hearing.
- Sourcing
- Low – the information comes from a single internal notice excerpt with no external corroboration, background, or independent verification.
- Framing
- The content consists solely of factual reporting of an FDA action and Amneal's request; no opinion or editorializing is present.
- Omissions
- The notice does not explain why Amneal requested the withdrawal, what regulatory or commercial factors prompted the decision, or what impact the withdrawal will have on patients, prescribers, or the market for celecoxib.
- Rhetorical notes (2)
- neutral factual statement · neutral factual statement
All coverage
FDA Withdraws Approval of Amneal’s Celecoxib Capsule ANDA at Manufacturer’s Request
1 source analyzed2 claims checked0 primary sourcesUpdated 4h ago
2 unverifiable
People in this coverage
Explore their history and attributable record. Being mentioned does not imply endorsement.
What happened
FactThe U.S. Food and Drug Administration announced the withdrawal of approval for abbreviated new drug application (ANDA) 208833 covering Celecoxib capsules in 50 mg, 100 mg, 200 mg, and 400 mg strengths, which were held by Amneal Pharmaceuticals of New York, LLC. According to the FDA notice, Amneal requested the withdrawal and waived its right to a hearing. The notice does not specify the reasons for the withdrawal, so the underlying cause remains unclear.
Layer 1 · Fact check
AI analysisEach claim below was extracted from the reporting and checked against independently retrieved evidence. Expand a claim to see the evidence trail and reasoning.
Layer 2 · Biblical perspective
Biblical interpretationProduced only after the factual analysis was complete. It examines the specific reported conduct — never a party, nation, or person as a whole — and never alters the factual findings above.
INSUFFICIENT CONTEXTFull biblical analysis
Moral topic
Withdrawal of drug approval for Celecoxib capsules by Amneal Pharmaceuticals
Biblical principle
When a situation lacks clear scriptural guidance on the specific action, the appropriate response is to acknowledge insufficient context for moral judgment.
Old Testament
No passages cited.
New Testament
No passages cited.
Explanation
The event concerns a regulatory and commercial decision with no documented conduct that can be evaluated against biblical moral teachings. No passage among the supplied candidates directly addresses the moral dimensions of withdrawing a drug application.
Why these passages apply
No supplied passage directly relates to the conduct of withdrawing a pharmaceutical approval; therefore, no verses are cited.
Interpretive limitations
Only the supplied verses may be used; none of them speak to corporate regulatory actions, so a moral classification cannot be determined from the available scriptural evidence.
Source comparison
AI analysisHow each publication covered the same event — facts included, sourcing quality, framing, and omissions.
Layer 3 · Reporting analysis
AI analysisneutral factual statement
seen in 2 articlesThe sentence presents the core action without evaluative language, indicating a straightforward report.
In Amneal Pharmaceuticals of New York, LLC; Withdrawal of Approval of Abbreviated New Drug Application for Celecoxib Capsules, 50 Milligrams, 100 Milligrams, 200 Milligrams, and 400 Milligrams · Federal Register
This sentence reports Amneal's procedural choice without commentary, maintaining a neutral tone.
In Amneal Pharmaceuticals of New York, LLC; Withdrawal of Approval of Abbreviated New Drug Application for Celecoxib Capsules, 50 Milligrams, 100 Milligrams, 200 Milligrams, and 400 Milligrams · Federal Register
Uncertainty
Where evidence is thin or reporting diverges, the fact-check entries above say so explicitly rather than manufacturing certainty. Claims marked “Unverifiable” or “Missing context” reflect genuine gaps in the available evidence, not editorial judgment.
Evidence
FactEvery source the pipeline retrieved, grouped by evidence tier. Repeated reporting of the same original claim is not counted as independent confirmation.
No evidence records published for this event yet.
Methodology
AI analysisThis analysis was produced by an automated daily pipeline: feeds are retrieved and normalized, URLs canonicalized, near-duplicates removed, and articles describing the same underlying event are clustered. Claims are extracted as atomic, testable propositions; evidence is retrieved in tiers from primary sources down to commentary; each claim is verified against that evidence; then reporting analysis and — separately — biblical analysis are performed. Every stage emits validated structured data, and any stage that fails validation is quarantined for human review instead of being published.
Publisher reputation, author reputation, and ideology never determine whether a factual claim is true. The biblical classifier examines only the specific reported conduct, and its result cannot change the factual findings.
AI disclosure
- AI-generated analysis.
- Evidence checked:
- 0
- Primary sources:
- 0
- Confidence:
- Low
- Last analyzed:
- Oct 9, 2026, 12:45 AM CDT
- Pipeline:
- 2.1.0
Articles in this event
Federal Register · Health, Drug Administration, Human Services Department, Food
Amneal Pharmaceuticals of New York, LLC; Withdrawal of Approval of Abbreviated New Drug Application for Celecoxib Capsules, 50 Milligrams, 100 Milligrams, 200 Milligrams, and 400 MilligramsOct 8, 2026, 11:00 PM CDTOriginal